Eli Lilly and NVIDIA announced a $1 billion co-innovation lab to accelerate AI-driven drug discovery, pairing NVIDIA’s BioNeMo and NeMo platforms with Lilly’s drug discovery teams. The partnership will build a Bay Area hub for model development, aiming to close the loop between computational predictions and wet-lab validation. Initial work will focus on integrating high-throughput computational screening with experimental automation to explore chemical and biological spaces in silico prior to synthesis. Jensen Huang (NVIDIA) framed the effort as “inventing a new blueprint for drug discovery” and said the lab will enable scientists to test many more hypotheses before making molecules. The investment underscores how large pharma and AI infrastructure vendors are formalizing joint R&D pipelines and will pressure competitors to accelerate their own ML-enabled discovery efforts and data partnerships.